We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Comparison of the efficiency of two different proton pump inhibitor formula in treatment of patients with atypical gastroesophageal reflux disease: a prospective randomized study.
- Authors
Lin, Xi‐Hsuan; Luo, Jiing‐Chyuan; Ting, Po‐Hsiang; Chang, Tien‐En; Huang, Yi‐Hsiang; Hou, Ming‐Chih; Lee, Fa‐Yauh
- Abstract
Background and Aim: The prospective, open‐label, randomized study aims to compare the efficacy of lansoprazole, a fast orally disintegrating proton pump inhibitor (PPI), and dexlansoprazole, a dual delayed release PPI, in patients with atypical symptoms of gastroesophageal reflux disease (GERD). Methods: Patients with atypical GERD symptoms with a total reflux symptom index score > 10 were eligible for enrollment. From February 2018 to December 2019, 232 subjects were randomly assigned (1:1 ratio) to receive oral lansoprazole, Takepron OD 30 mg, once daily before breakfast or oral dexlansoprazole, Dexilant 60 mg, once daily before breakfast for 8 weeks. The primary end‐point is to compare the symptoms response rate after an 8‐week PPI therapy between the two groups. Results: There were 232 study subjects enrolling in this study. After the 8‐week PPI therapy, dexlansoprazole‐treated group had a significantly higher response rate than lansoprazole‐treated group in cough (76.5% vs 38.0%) and globus (69.7% vs 30.8%) (P all < 0.05 by intention‐to‐treat). Multivariate logistic regression analysis showed that the use of dexlansoprazole, presence of dyslipidemia, and typical GERD symptoms (acid reflux and heartburn) were predictors for symptom response for cough; the use of dexlansoprazole and presence of erosive esophagitis were predictors for symptom response for globus (P all < 0.05). No predictor for therapy response to hoarseness was noted. Conclusions: There is a higher response rate for cough and globus symptoms in patients with atypical GERD after the 8‐week PPI therapy with dexlansoprazole rather than lansoprazole.
- Subjects
PROTON pump inhibitors; GASTROESOPHAGEAL reflux; SYMPTOMS; LOGISTIC regression analysis; LONGITUDINAL method
- Publication
Journal of Gastroenterology & Hepatology, 2020, Vol 35, Issue 12, p2096
- ISSN
0815-9319
- Publication type
Article
- DOI
10.1111/jgh.15093